The spice-derived phenolic,
malabaricone B (mal B) showed selective toxicity to human
lung cancer (A549),
malignant melanoma (A375) and
T cell leukemia (Jurkat) cell lines, without showing toxicity to human normal intestinal (INT407), human kidney (HEK293) and lung fibroblast (WI-38) cells. Among the chosen
cancer cell lines, mal B showed maximum cytotoxicity to the A549 cells (IC50 = 8.1 ± 1.0 μM), which was significantly better than that of
curcumin (IC50 = 26.7 ± 3.1 μM). Further morphological studies by phase contrast microscopy and a clonogenic assay of the A549 cells revealed that mal B treatment increased the number of shrinking cells and also abolished the clonal proliferation of the cells. Mal B induced apoptotic cell death was confirmed by
DNA laddering and quantified by cytoplasmic oligonucleosome formation and
annexin V/PI assays. The mal B-induced apoptosis was mediated by an increase in the intracellular
reactive oxygen species (ROS), because the cell-permeable
antioxidants,
N-acetylcysteine (NAC) and
PEG-SOD, strongly inhibited its cytotoxicity to the A549 cells. Mal B increased the BAX level while simultaneously decreasing the BCL-2 and BCL-XL levels in the A549 cells, triggering the mitochondrial apoptotic pathway as revealed from the release of
cytochrome c, and the activation of
caspase-9 and
caspase-3. Pre-treatment of cells with
caspase-9,
caspase-3 and pan-
caspase inhibitors made them more resistant to mal B treatment. This effect of mal B was strongly associated with the concomitant decrease in anti-apoptotic (IAP1, IAP2 and
survivin), angiogenic (
growth factors) and
cancer invasiveness (matrix metalloproteinase-9, COX-2) modulating
proteins. Mal B induced cytotoxicity was unaffected by the
shRNA-mediated depletion of p53 in A549 cells. Most importantly, mal B sensitized a wide range of human
carcinoma cells regardless of their p53 status. Finally, mal B (100 mg kg-1) also inhibited lung
tumor (xenograft) growth in SCID mice.